Basel, May 5, 2011 - Novartis announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease.